Evidence map›Paper›PMID 24752077›Full record

ArticleNature biotechnology2014

GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins.

Leander Meuris, Francis Santens, Greg Elson, Nele Festjens, Morgane Boone, Anaëlle Dos Santos, Simon Devos, François Rousseau, Evelyn Plets, Erica Houthuys and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 148 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Construction of anFrontiers in bioengineering and biotechnology · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Leander Meuris1] Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium. [2] Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium. [3].
Francis Santens1] Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium. [2] Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium. [3].
Greg Elson1] NovImmune SA, Plan-Les-Ouates, Geneva, Switzerland. [2].
Nele Festjens1] Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium. [2] Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Morgane Boone1] Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium. [2] Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Anaëlle Dos SantosNovImmune SA, Plan-Les-Ouates, Geneva, Switzerland.
Simon DevosLaboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
François RousseauNovImmune SA, Plan-Les-Ouates, Geneva, Switzerland.
Evelyn Plets1] Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium. [2] Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Erica Houthuys1] Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium. [2] Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Pauline MalingeNovImmune SA, Plan-Les-Ouates, Geneva, Switzerland.
Giovanni MagistrelliNovImmune SA, Plan-Les-Ouates, Geneva, Switzerland.
Laura ConsNovImmune SA, Plan-Les-Ouates, Geneva, Switzerland.
Laurence ChatelNovImmune SA, Plan-Les-Ouates, Geneva, Switzerland.
Bart DevreeseLaboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Nico Callewaert1] Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium. [2] Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Light Chain Bioscience (Switzerland) · CHVIB-UGent Center for Inflammation Research · BEGhent University · BE

Funding

European Research Council 616966
6 · The paper itself

Abstract

Heterogeneity in the N-glycans on therapeutic proteins causes difficulties for protein purification and process reproducibility and can lead to variable therapeutic efficacy. This heterogeneity arises from the multistep process of mammalian complex-type N-glycan synthesis. Here we report a glycoengineering strategy--which we call GlycoDelete--that shortens the Golgi N-glycosylation pathway in mammalian cells. This shortening results in the expression of proteins with small, sialylated trisaccharide N-glycans and reduced complexity compared to native mammalian cell glycoproteins. GlycoDelete engineering does not interfere with the functioning of N-glycans in protein folding, and the physiology of cells modified by GlycoDelete is similar to that of wild-type cells. A therapeutic human IgG expressed in GlycoDelete cells had properties, such as reduced initial clearance, that might be beneficial when the therapeutic goal is antigen neutralization. This strategy for reducing N-glycan heterogeneity on mammalian proteins could lead to more consistent performance of therapeutic proteins and modulation of biopharmaceutical functions.

Indexed as

AnimalsGlycosylationHumansMicePolysaccharidesProtein EngineeringRecombinant ProteinsPolysaccharidesRecombinant Proteins

Identifiers

PMID24752077
PMCPMC7039703
OpenAlexW1965443132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.